FasTCAR Cell Therapy Granted Orphan Drug Designation for Multiple Myeloma

The designation follows durable responses seen in a phase 1 study of the agent.

Overcoming Challenges With CAR T Therapies in Solid Tumors: Julian Molina, MD, PhD

The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in a variety of cancers.

FDA Accepts Beti-Cel BLA for β-thalassemia

The investigational gene therapy, which will receive priority review, has a PDUFA date of May 20, 2022.

Gene Therapy for Parkinson Disease Demonstrates Safety, Improved Motor Function

From baseline, all participants showed improvements on CGI-Improvement scale scores while all but 1 patient demonstrated improvement on modified Hoehn and Yahr scores.

Cilta-Cel is Well-Tolerated with Durable Efficacy in R/R Multiple Myeloma

The recommended phase 2 dose of cilta-cel elicited deep and durable responses, along with a tolerable safety profile.

CAR T-Cell Therapy's Continued Benefit in B-Cell Non-Hodgkin Lymphoma

Positive data has been seen with CAR T-cell therapy in patients with indolent lymphoma.